Research statistics

Davunetide research: publications and trials

What has been published on Davunetide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Davunetide works or is safe. For what it is and what the studies found, see the Davunetide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

174

Since 1999

Publications in 2026 so far

7

Through November 15, 2026

Human clinical research

8.1%

14 of 173 classified

Registered clinical trials

5

ClinicalTrials.gov

Randomized controlled trials

9

Publications reporting an RCT in people

Systematic reviews and meta-analyses

1

Preclinical studies

72.8%

104 animal · 21 in vitro · 1 computational

Records that only mention it

46

Not counted above

Status in the library: In clinical trials. Groups: Cognitive and neurological peptides. 1 publications are not yet classified by study type.

What to keep in mind

  • More than 70% of the indexed publications are animal, cell or computational studies.
  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Davunetide publications by year and evidence

1999, Preclinical (animal, in vitro, computational): 1 of 21999, Reviews and meta-analyses: 1 of 22000, Preclinical (animal, in vitro, computational): 3 of 32001, Preclinical (animal, in vitro, computational): 2 of 22002, Preclinical (animal, in vitro, computational): 5 of 52003, Preclinical (animal, in vitro, computational): 3 of 42003, Reviews and meta-analyses: 1 of 42004, Preclinical (animal, in vitro, computational): 5 of 52005, Preclinical (animal, in vitro, computational): 8 of 92005, Reviews and meta-analyses: 1 of 92006, Preclinical (animal, in vitro, computational): 9 of 112006, Reviews and meta-analyses: 2 of 112007, Preclinical (animal, in vitro, computational): 10 of 112007, Reviews and meta-analyses: 1 of 112008, Preclinical (animal, in vitro, computational): 6 of 72008, Reviews and meta-analyses: 1 of 72009, Preclinical (animal, in vitro, computational): 9 of 102009, Reviews and meta-analyses: 1 of 102010, Preclinical (animal, in vitro, computational): 8 of 102010, Reviews and meta-analyses: 2 of 102011, Human clinical research: 1 of 112011, Preclinical (animal, in vitro, computational): 6 of 112011, Reviews and meta-analyses: 4 of 112012, Preclinical (animal, in vitro, computational): 5 of 82012, Reviews and meta-analyses: 3 of 82013, Human clinical research: 3 of 102013, Preclinical (animal, in vitro, computational): 5 of 102013, Reviews and meta-analyses: 2 of 102014, Human clinical research: 2 of 122014, Preclinical (animal, in vitro, computational): 8 of 122014, Reviews and meta-analyses: 1 of 122014, Other and not yet classified: 1 of 122015, Preclinical (animal, in vitro, computational): 2 of 22016, Human clinical research: 1 of 92016, Preclinical (animal, in vitro, computational): 4 of 92016, Reviews and meta-analyses: 3 of 92016, Other and not yet classified: 1 of 92017, Human clinical research: 1 of 72017, Preclinical (animal, in vitro, computational): 6 of 72018, Preclinical (animal, in vitro, computational): 1 of 12019, Preclinical (animal, in vitro, computational): 5 of 62019, Reviews and meta-analyses: 1 of 62020, Human clinical research: 1 of 32020, Reviews and meta-analyses: 1 of 32020, Other and not yet classified: 1 of 32021, Preclinical (animal, in vitro, computational): 2 of 32021, Reviews and meta-analyses: 1 of 32022, Human clinical research: 1 of 32022, Preclinical (animal, in vitro, computational): 1 of 32022, Reviews and meta-analyses: 1 of 32023, Human clinical research: 1 of 32023, Preclinical (animal, in vitro, computational): 2 of 32024, Human clinical research: 1 of 72024, Preclinical (animal, in vitro, computational): 6 of 72025, Human clinical research: 1 of 32025, Reviews and meta-analyses: 1 of 32025, Other and not yet classified: 1 of 32026 (to date), Human clinical research: 1 of 72026 (to date), Preclinical (animal, in vitro, computational): 4 of 72026 (to date), Reviews and meta-analyses: 2 of 7Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified05101519992005201120172026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
199901102
200003003
200102002
200205005
200303104
200405005
200508109
2006092011
20070101011
200806107
2009091010
2010082010
2011164011
201205308
2013352010
2014281112
201502002
201614319
201716007
201801001
201905106
202010113
202102103
202211103
202312003
202416007
202510113
2026 (to date)14207

Study types

Animal study104
Review29
In vitro study21
Randomized controlled trial9
Observational human study4
Editorial, letter or other3
Case report1
Computational study1
Meta-analysis1
Not yet classified1

Research areas

From MeSH major topics. A paper can be in several areas.

Neurological and mental health148
Cognitive health45
Reproductive and sexual health16
Cardiovascular11
Endocrinology9
Metabolic health8
Tissue repair7
Musculoskeletal4
Immune system2
Longevity and aging2
Antimicrobial and infectious disease1
Dermatology1

Registered clinical trials

1 of 5 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 5
Phase 1: 1 · Phase 2: 3 · Phase 2 / Phase 3: 1

TrialStatusPhaseStartedResults
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyNCT01110720 · 313 enrolledCompletedPhase 2, Phase 32010-10—
Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyNCT01056965 · 12 enrolledCompletedPhase 12010-01—
A Multicenter Study of NAP (AL-108) in SchizophreniaNCT00505765 · 63 enrolledCompletedPhase 22007-07Posted
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive ImpairmentNCT00422981 · 144 enrolledCompletedPhase 22007-01—
Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft SurgeryNCT00404014 · 234 enrolledCompletedPhase 22006-08—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.

    Psychological medicine · August 23, 2019 · Meta-analysis · cited 216 times · open access

    PMID 31439071 · DOI 10.1017/s0033291719001995 · Reviews and meta-analyses

  2. Systemic davunetide provides sex-specific neuroprotection during Coronary Artery Bypass Grafting (CABG).

    Translational psychiatry · October 31, 2025 · Randomized controlled trial · cited 5 times · open access

    PMID 41173865 · DOI 10.1038/s41398-025-03675-y · Human clinical research

  3. Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease.

    Translational psychiatry · October 2, 2024 · Randomized controlled trial · cited 26 times · open access

    PMID 39358355 · DOI 10.1038/s41398-024-03118-0 · Human clinical research

  4. Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women.

    Translational psychiatry · October 16, 2023 · Randomized controlled trial · cited 26 times · open access

    PMID 37845254 · DOI 10.1038/s41398-023-02618-9 · Human clinical research

  5. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.

    Neurology · December 27, 2017 · Randomized controlled trial · cited 112 times · open access

    PMID 29282336 · DOI 10.1212/wnl.0000000000004859 · Human clinical research

  6. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.

    Movement disorders : official journal of the Movement Disorder Society · October 1, 2016 · Randomized controlled trial · cited 21 times · open access

    PMID 27324431 · DOI 10.1002/mds.26694 · Human clinical research

  7. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

    The Lancet. Neurology · May 27, 2014 · Randomized controlled trial · cited 295 times · open access

    PMID 24873720 · DOI 10.1016/s1474-4422(14)70088-2 · Human clinical research

  8. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.

    Dementia and geriatric cognitive disorders · April 13, 2013 · Randomized controlled trial · cited 115 times

    PMID 23594991 · DOI 10.1159/000348347 · Human clinical research

  9. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · January 16, 2013 · Randomized controlled trial · cited 67 times · open access

    PMID 23325325 · DOI 10.1038/npp.2013.23 · Human clinical research

  10. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

    Schizophrenia research · December 12, 2011 · Randomized controlled trial · cited 118 times

    PMID 22169248 · DOI 10.1016/j.schres.2011.11.001 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide.

    Journal of neurochemistry · March 1, 1999 · Animal study · cited 394 times

    PMID 10037502 · DOI 10.1046/j.1471-4159.1999.0721283.x · Animal studies

  2. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

    The Lancet. Neurology · May 27, 2014 · Randomized controlled trial · cited 295 times · open access

    PMID 24873720 · DOI 10.1016/s1474-4422(14)70088-2 · Human clinical research

  3. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

    The Journal of pharmacology and experimental therapeutics · August 24, 2007 · Animal study · cited 219 times

    PMID 17720885 · DOI 10.1124/jpet.107.129551 · Animal studies

  4. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.

    Biomaterials · February 27, 2013 · Animal study · cited 217 times

    PMID 23453061 · DOI 10.1016/j.biomaterials.2013.02.003 · Animal studies

  5. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.

    Psychological medicine · August 23, 2019 · Meta-analysis · cited 216 times · open access

    PMID 31439071 · DOI 10.1017/s0033291719001995 · Reviews and meta-analyses

Latest publications

  1. NAP peptide modulated proteome profiling of rat brain cortex under hypobaric hypoxia.

    Respiratory physiology & neurobiology · September 11, 2026 · Animal study · cited 0 times

    PMID 42727869 · DOI 10.1016/j.resp.2026.104648 · Animal studies

  2. Dramatic sex differences leading to different brain disease presentation: The requirement for sex-specific medications with ADNP/davunetide as a case study.

    Frontiers in neuroendocrinology · August 10, 2026 · Review · cited 0 times · open access

    PMID 42575342 · DOI 10.1016/j.yfrne.2026.101274 · Reviews and meta-analyses

  3. Complement C3 inhibitory peptide AMY-101 ameliorates brain injury in a mouse model of NMOSD.

    Annals of medicine · August 7, 2026 · Animal study · cited 0 times · open access

    PMID 42568287 · DOI 10.1080/07853890.2026.2705007 · Animal studies

  4. Activity-dependent neuroprotective protein (ADNP) derived peptide NAP prevents musculoskeletal abnormalities in ovariectomized mice.

    Frontiers in neuroscience · July 28, 2026 · Animal study · cited 0 times · open access

    PMID 42582414 · DOI 10.3389/fnins.2026.1891428 · Animal studies

  5. ADNP Functions During Early Brain Development and Their Relevance to ASD and ADNP Syndrome.

    International journal of molecular sciences · July 7, 2026 · Review · cited 2 times · open access

    PMID 42450350 · DOI 10.3390/ijms27136085 · Reviews and meta-analyses

  6. Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.

    Molecular psychiatry · July 3, 2026 · Observational human study · cited 1 times · open access

    PMID 42399413 · DOI 10.1038/s41380-026-03709-x · Human clinical research

  7. Activity dependent neuroprotective protein mediates the protective effects against VEGF-induced corneal barrier disruption in diabetes.

    Peptides · April 7, 2026 · Animal study · cited 0 times

    PMID 41956253 · DOI 10.1016/j.peptides.2026.171488 · Animal studies

  8. Systemic davunetide provides sex-specific neuroprotection during Coronary Artery Bypass Grafting (CABG).

    Translational psychiatry · October 31, 2025 · Randomized controlled trial · cited 5 times · open access

    PMID 41173865 · DOI 10.1038/s41398-025-03675-y · Human clinical research

  9. Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity.

    Advanced drug delivery reviews · April 2, 2025 · Review · cited 12 times · open access

    PMID 40185278 · DOI 10.1016/j.addr.2025.115573 · Reviews and meta-analyses

  10. Davunetide promotes structural and functional recovery of the injured spinal cord by promoting autophagy.

    Neural regeneration research · March 25, 2025 · Not yet classified · cited 22 times · open access

    PMID 40145989 · DOI 10.4103/nrr.nrr-d-24-00154 · Not yet classified

Browse all 174 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: AL-108; AL-208; Davunetida; Davunetide; NAPVSIPQ

((TITLE_ABS:"AL-108" OR CHEM:"AL-108" OR TITLE_ABS:"AL108" OR CHEM:"AL108") OR (TITLE_ABS:"AL-208" OR CHEM:"AL-208" OR TITLE_ABS:"AL208" OR CHEM:"AL208") OR (TITLE_ABS:"Davunetida" OR CHEM:"Davunetida") OR (TITLE_ABS:"Davunetide" OR CHEM:"Davunetide") OR (TITLE_ABS:"NAPVSIPQ" OR CHEM:"NAPVSIPQ")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Davunetide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/davunetide